Galapagos is flush with billions in cash, but it’s not moving forward with its own pipeline. So what’s the Belgian biotech going to do with

BioMarin plans to dish out $4.8 billion to acquire Amicus Therapeutics and its two approved rare disease medicines, the California biotech said Friday. By gaining

Plus, news on: EpimAb, Boehringer and Nxera, Syneron, Amphix Altimmune goes to Phase 3 in MASH: The drug developer’s Phase 2 trial of pemvidutide, a

The BIOSECURE Act, now part of the NDAA, will put in motion US government-wide restrictions on ‘biotechnology companies of concern’.

Aditum Bio, the biotech company creation firm from former Novartis leaders Joe Jimenez and Mark Fishman, has returned to China for another deal. This time,